IPN Therapy for Peritoneal Dialysis Patients: How It Works and Who Qualifies

June 25, 2026

Malnutrition is a serious and common complication in patients on peritoneal dialysis (PD). Unlike hemodialysis, where IDPN can be delivered through the dialysis circuit, peritoneal dialysis patients require a different nutritional intervention, one that works with their existing PD routine rather than requiring additional IV access.


Intraperitoneal nutrition (IPN) fills that role. Pharmko provides individually compounded IPN solutions to patients on peritoneal dialysis across 22+ states, working directly with nephrology teams and renal dietitians to evaluate eligibility and coordinate delivery.


What Is Intraperitoneal Nutrition?


IPN is a specialized amino acid solution that is added to, or substituted for, one or more standard peritoneal dialysis exchanges per day. Instead of using a standard dextrose-based dialysate, the patient instills an amino acid-enriched solution into the peritoneal cavity, where it dwells for the prescribed time before draining.


During the dwell, amino acids are absorbed directly across the peritoneal membrane into the systemic circulation, bypassing the GI tract entirely. This makes IPN particularly valuable for patients with concurrent GI dysfunction, poor appetite, or protein malabsorption that limits the effectiveness of oral or enteral nutritional support.


IPN is compatible with both continuous ambulatory peritoneal dialysis (CAPD) and continuous cycling peritoneal dialysis (CCPD). It requires no additional needle sticks, no IV access, and no changes to the patient's existing PD schedule, the amino acid solution simply replaces one standard exchange.


Why Peritoneal Dialysis Patients Are at Nutritional Risk


Patients with end-stage renal disease (ESRD) on peritoneal dialysis lose an average of 5 to 15 grams of protein per day through the peritoneal membrane during each dialysis exchange. This ongoing, unavoidable protein loss occurs even when patients follow their prescribed diets carefully. Over time, cumulative protein loss leads to:


  • Declining serum albumin and pre-albumin, key markers of nutritional status and mortality risk
  • Muscle wasting and progressive loss of lean body mass
  • Reduced immune function and increased susceptibility to peritonitis and other infections
  • Poor wound healing, fatigue, and reduced quality of life
  • Higher rates of hospitalization and all-cause mortality


Standard dietary counseling and oral nutritional supplementation often fail to fully compensate for these losses, particularly in patients with uremia-related anorexia or gastrointestinal symptoms. IPN provides direct amino acid repletion that bypasses the barriers to oral absorption.


Who Qualifies for IPN?


IPN eligibility is based on documented protein-energy wasting or malnutrition in a patient already receiving peritoneal dialysis, where conventional nutritional interventions have been insufficient. Clinical criteria typically include:


  • Serum albumin below 3.5 g/dL or pre-albumin below 30 mg/dL
  • Documented inadequate protein intake despite dietary counseling
  • Failure to respond to oral nutritional supplementation after a defined trial
  • Adequate peritoneal transport characteristics to support amino acid absorption
  • Absence of contraindications to peritoneal amino acid infusion (e.g., active peritonitis)


The nephrologist and renal dietitian determine eligibility in collaboration with Pharmko's clinical team. For a parallel review of nutritional support in hemodialysis patients, see our guide on malnutrition in hemodialysis patients and IDPN.


IPN vs IDPN: Key Differences


Both IPN and IDPN address malnutrition in dialysis patients, but they serve different patient populations and are delivered through entirely different routes:


  • IDPN is for hemodialysis patients, delivered IV through the dialysis blood circuit during hemodialysis sessions
  • IPN is for peritoneal dialysis patients, delivered intraperitoneally, substituting one PD exchange per day
  • IDPN provides amino acids, dextrose, and lipids; IPN provides amino acids, with dextrose from the dialysate serving the caloric function
  • Neither requires GI absorption, both bypass the gut entirely


The full spectrum of Pharmko's dialysis and renal nutrition services covers all three modalities: IDPN, IPN, and TPN.


How Pharmko Delivers IPN


Referral and clinical review


The nephrologist or renal dietitian submits a referral with supporting labs (albumin, pre-albumin, dietary history) and PD prescription details. Pharmko's clinical pharmacist reviews eligibility and works with the prescribing team to confirm the amino acid formula and exchange substitution schedule.


Compounding and delivery


Each IPN solution is individually compounded by Pharmko's pharmacy team in a USP <797> compliant sterile environment and delivered directly to the patient's home on a scheduled cycle. Solutions are cold-chain validated for stability through the planned dwell period.


Monitoring and formula adjustment


Pharmko monitors labs at regular intervals and adjusts the IPN formula in coordination with the nephrologist and dietitian, ensuring the nutritional plan remains aligned with the patient's evolving clinical status.


Contact Pharmko to refer a peritoneal dialysis patient: 1-877-540-2003


Person living with end stage renal disease going about an ordinary morning at home
September 1, 2026
Straight answers to what people on dialysis ask most: nutrition, phosphate, energy, travel, and the emotional weight of ongoing treatment.
Handwritten list of questions prepared for a dialysis appointment about IDPN therapy
September 1, 2026
The questions worth bringing to your nephrologist or dietitian before starting intradialytic parenteral nutrition, grouped and ready to print.
Adult daughter and her mother reviewing a delivery schedule together in the kitchen at home
September 1, 2026
A practical guide for caregivers: what your role is, what the pharmacy can share with you, what to keep track of, and how to protect your own energy.
Family sharing a meal at home while one member on parenteral nutrition joins the table
September 1, 2026
Whether you can eat on parenteral nutrition, why appetite and taste change, and how to handle meals with family while receiving IV nutrition.
Suitcase packed with a small cooler and paperwork for traveling while on parenteral nutrition
August 31, 2026
How to plan a trip on TPN or home parenteral nutrition: supplies, refrigeration, air travel documentation, and how far ahead to call your pharmacy.
Home delivery of TPN supplies unpacked on a kitchen table during the first week of therapy
August 31, 2026
A day-by-day look at starting total parenteral nutrition at home: the first delivery, the first infusion, night one, and when to call for help.
Dialysis center staff coordinating phosphate binder supply with a pharmacy partner
August 11, 2026
What dialysis centers should look for in a phosphate binder supply partner: reliable delivery, formulary breadth, insurance support, and coordination.
Renal dietitian reviewing phosphate levels with a dialysis patient
August 11, 2026
How hyperphosphatemia is managed in ESRD dialysis patients, diet, dialysis, and phosphate binders, and why reliable binder supply keeps therapy on track.
July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Show More